GLP-1 agonists
Showing 1 - 25 of >10,000
Gastric Ultrasound Assessment for Patients Taking GLP1 Agonists
Not yet recruiting
- Gastric Ultrasound
- +2 more
- Gastric Ultrasound Exam
- (no location specified)
Aug 15, 2023
Morbid Obesity, Metabolic Syndrome, Diabetes Trial in Columbia (GLP-1 receptor agonist)
Not yet recruiting
- Morbid Obesity
- +4 more
- GLP-1 receptor agonist
-
Columbia, MissouriUniversity of Missouri Hospital
Nov 20, 2023
Type II Diabetes Trial in Dijon (drug, procedure, other)
Recruiting
- Type II Diabetes
- GLP-1 agonists
- +2 more
-
Dijon, FranceChu Dijon Bourgogne
Jan 2, 2023
Delayed Gastric Emptying, Gastroparesis Trial in Chapel Hill (gastric ultrasound)
Not yet recruiting
- Delayed Gastric Emptying
- Gastroparesis
- gastric ultrasound
-
Chapel Hill, North CarolinaUniversity of North Carolina Medical Center
Sep 8, 2023
Effects of GLP-1 Agonists on Gastric Volume
Not yet recruiting
- Diabetes
- +3 more
- Gastric Ultrasound
-
Charleston, South CarolinaMedical University of South Carolina
May 10, 2023
Type 1 Diabetes Trial (Semaglutide weekly injection)
Not yet recruiting
- Type 1 Diabetes
- Semaglutide weekly injection
- (no location specified)
Sep 21, 2023
Diabetes Trial in Nanjing (Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc)
Recruiting
- Diabetes
- Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc
-
Nanjing, ChinaNanjing First Hospital, Nanjing Medical Univesity
Aug 6, 2023
Glucagon-like Peptide-1 Receptor Agonists According to Type 2
Recruiting
- Diabetes Mellitus, Type 2
- GLP-1 receptor agonist
-
Bari, ItalyAzienda Ospedaliero-Universitaria Policlinico Bari
Nov 4, 2023
Type 2 Diabetes Trial in Lancaster (Exenatide Injection, Saline injection)
Terminated
- Type 2 Diabetes
- Exenatide Injection
- Saline injection
-
Lancaster, PennsylvaniaAmish Research Clinic
Mar 6, 2023
Preoperative Prandial State of Patients Taking Glucagon-Like
Recruiting
- Pulmonary Aspiration
- Gastric ultrasound
-
Houston, TexasThe University of Texas Health Science Center at Houston
Jun 6, 2023
Osteoporosis, Postmenopausal, Diabetes, Type 2 Trial in Jackson (GLP-1 receptor agonist)
Recruiting
- Osteoporosis, Postmenopausal
- Diabetes Mellitus, Type 2
- GLP-1 receptor agonist
-
Jackson, MississippiUniversity of Mississippi Medical Center
Aug 5, 2022
Glucagon-like Peptide 1 Receptor Agonists and Mental Health
Not yet recruiting
- Diabetes Mellitus
- +2 more
- GLP-1 receptor agonist
- (no location specified)
Aug 4, 2022
GLP-1RAs) and SGLT2is Combination Therapy and MACEs in Type 2
Recruiting
- Diabetes Mellitus, Type 2
- Myocardial Infarction
- PCI
-
Naples, ItalyCelestino Sardu
Aug 31, 2023
Obesity, Diabetes Type 2 Trial in Lancaster (Semaglutide Pen Injector [Ozempic])
Recruiting
- Obesity
- Diabetes Type 2
- Semaglutide Pen Injector [Ozempic]
-
Lancaster, PennsylvaniaAmish Research Clinic
Jul 29, 2022
Aging, Diabetes, Type 2, PreDiabetes Trial in San Antonio (Semaglutide Injectable Product, Lifestyle Counseling)
Recruiting
- Aging
- +3 more
- Semaglutide Injectable Product
- Lifestyle Counseling
-
San Antonio, TexasUT Health San Antonio
Apr 3, 2023
Diabetes, Type 2 Trial in Danville (Semaglutide (1 Mg Dose), Placebo)
Recruiting
- Diabetes Mellitus, Type 2
- Semaglutide (1 Mg Dose)
- Placebo
-
Danville, PennsylvaniaGeisinger Medical Center
Sep 9, 2021
SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS ,
Active, not recruiting
- Weight Loss
- +3 more
- GLP-1 receptor agonist
-
Culleredo, A Coruña, Spain
- +10 more
Jan 13, 2023
Type 2 Diabetes Trial in Xuzhou (GLP-1 receptor agonist)
Recruiting
- Type 2 Diabetes Mellitus
- GLP-1 receptor agonist
-
Xuzhou, Jiangsu, ChinaDepartment of Endocrinology
Apr 16, 2022
Based on Data From German Sick Funds That Looks at Costs of
Completed
- Diabetes Mellitus, Type 2
- Empagliflozin
- +3 more
-
Ingelheim am Rhein, GermanyBoehringer Ingelheim
Jan 18, 2022
Therapeutic Drug Use for CKD Patients
Active, not recruiting
- Chronic Kidney Disease
- angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker
-
Jinan, Shandong, ChinaXiao Li,MD
Apr 18, 2023
A Pan-European Post-Authorisation Safety Study: Risk of
Not yet recruiting
- Pancreatic Cancer
- Exenatide
- Non-GLP-1 RA based glucose lowering drugs
- (no location specified)
Dec 21, 2022
Anti-obesity Pharmacotherapy and Inflammation
Not yet recruiting
- Obesity
- Liraglutide or Semaglutide
- Phentermine-Topiramate combination
-
New Orleans, Louisiana
- +1 more
Mar 3, 2023
Chronic Kidney Diseases Trial in Nashville (dulaglutide injection)
Recruiting
- Chronic Kidney Diseases
- dulaglutide injection
-
Nashville, TennesseeVanderbilt University Medical Center
Mar 20, 2022
Type 2 Diabetes, Coronary Artery Disease Trial in Athens (Liraglutide, Metformin)
Completed
- Type 2 Diabetes Mellitus
- Coronary Artery Disease
-
Athens, Attiki, Greece''Attikon'' University General Hospital
Mar 3, 2021